Protalix BioTherapeutics, Inc. (NYSE: PLX)

Protalix BioTherapeutics, Inc. (PLX) is a commercial-stage biopharmaceutical company operating in the biotechnology industry. The company specializes in the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system.

Protalix's primary business activities revolve around the development and commercialization of its proprietary products, including Elelyso and Elfabrio, which are used to treat Gaucher disease and Fabry disease, respectively. The company operates in the biotechnology industry, focusing on the development and commercialization of biopharmaceuticals, including recombinant proteins, vaccines, and gene therapies. Protalix's operations span across various countries and regions, including the United States, Brazil, Israel, and several European markets.

The company generates revenue through the sale of its products, primarily Elelyso and Elfabrio, to pharmaceutical companies and hospitals. Elelyso is a recombinant enzyme used to treat Gaucher disease, a rare genetic disorder affecting the production of an enzyme called glucocerebrosidase. Elfabrio, on the other hand, is a recombinant enzyme used to treat Fabry disease, which is caused by a deficiency in the alpha-galactosidase-A enzyme.

Protalix holds a competitive advantage in the industry due to its ProCellEx platform, which provides several benefits. These advantages include biologic optimization, the ability to handle complex protein expressions, flexible manufacturing with improvements through efficiencies, enhancements, and rapid horizontal scale-ups, a simplified production process, elimination of the risk of viral contaminations from mammalian components, and intellectual property advantages.

In the Gaucher disease market, Protalix's main competitors include Sanofi Genzyme, Takeda Pharmaceutical Company Limited, and Shire plc. In the Fabry disease market, the company's primary competitors are agalsidase beta, Sanofi Genzyme, Takeda Pharmaceutical Company Limited, and Shire plc.

Protalix's customers include pharmaceutical companies, hospitals, and research institutions. The company's primary customers are Pfizer, Chiesi, and Fiocruz, which have partnered with Protalix to commercialize its products.

In addition to its commercial products, Protalix is also developing several product candidates, including PRX-102, a recombinant PEGylated uricase enzyme for the treatment of severe gout, and PRX-119, a plant cell-expressed PEGylated recombinant human DNaseI product candidate for the treatment of NETs-related diseases.

Protalix's success is built on a robust patent portfolio, which is a key element of its overall strategy. The company has approximately 90 patents globally, including in Europe, the United States, Israel, and additional countries worldwide. Protalix also has approximately 50 pending patent applications.